|
Our team of experts begins with highly trained PhD and MS scientists
from around the world. A majority of CrownBioscience
scientists bring deep understanding of pharmaceutical
industry having lead major departments within the top
US pharmaceutical R&D and pre-clinical programs.Crown
Bio scientists engage in the design and execution of
your preclinical drug development program using our
AAALAC approved animal facilities, proprietary animal
models, and in vivo surgical expertise. This results
in fast delivery, cost-effective preclinical research
services for pharmaceutical, biopharma and medical device
companies
Senior management
Alex Wu, Ph.D.- Chief
Executive Officer
Dr. Alex Wu has over 20 years of experience
in the biopharmaceutical industry and research. Before
co-founding Crown Bioscience, he was CBO of Starvax,
Inc., a biopharmaceutical R&D company. Prior
to Starvax, he was the Head of Asian Operations with
Burrill & Company, a life science venture capital
and merchant bank. He also co-founded and was COO of
Unimicro Technologies, a life science instrumentation
company. Dr. Wu started his career with Hoffmann-La
Roche, where he was manager of business development
and strategic planning. Dr. Wu obtained his B.S. in
biochemistry from Fudan University, China and Ph.D.
and MBA from University of California at Berkeley.
Faming Zhang PhD. - President
Prior to joining Crown,
Dr. Zhang has spent 12 years at Eli Lilly & Co.
While at Lilly, he served as Global Head of Drug Discovery
and Development, Statistics and Information Sciences.
Prior to that, Dr. Zhang led Lilly’s protein kinase/phosphatase
crystal structure platform. He is the co-inventor of
several patents in the area of kinase inhibitors and
novel anti-obesity protein therapeutics. He also played
a major role in the progression of cell cycle kinase
inhibitors to the clinic. Dr. Zhang received his Ph.D
in Biochemistry and Molecular Biology from Inst. of
Biophysics, Chinese Academy of Sciences and an MBA from
Kelly Business School, Indiana University. He had 4
year of postdoctoral training in Protein Crystallography
from U. of Texas Southwestern Medical Center in Dallas.
He is also an Assoc. Professor of Chemistry and Biochemistry
at Indiana University. Dr. Zhang has authored more than
30 scientific publications.
Yiyou Chen, Ph.D.- Chief
Scientific Officer
Dr. Chen has over a decade of experience
in drug R&D. Prior to co-founding Crown Bioscience
Inc., he was Chief Scientific Officer and Co-founder
of Starvax Inc., a biopharmaceutical company developing
novel therapeutics against cancer and infectious disease.
Before founding Starvax, Dr. Chen was a senior scientist
and project leader at Palo Alto-based biotech company,
Genencor International Inc., involved in research projects
in animal modeling, protein engineering, and Immunology.
Dr. Chen obtained his PhD in Experimental Pathology
from University of Utah, and BS in Biochemistry from
Peking University.
William Pan, Ph.D.- President,
Crown Bioscience Inc. (Beijing)
Dr. William Pan obtained his B.S. in
Biology from Sun Yat-sen University, Ph.D. in Molecular
Biology from Sussex University, and had his postdoctoral
training in University of California at Berkeley.
He has more than 18 years of experiences in biopharmaceutical
research and development and is a co-founder of Crown
Bioscience Inc.. Dr. Pan was a research scientist and
project leader at TerraGen Discovery Inc. (later acquired
by Cubist Pharmaceuticals Inc.), and thereafter he co-founded
and served as General Manager of TsingYuan TongMao Biotechnology
Inc. in ShenZhen, China. Dr. Pan has also served
as vice president of TsingHua YuanXing Biopharmaceutical
Science and Technology Co., Inc., another ShenZhen-based
biopharmaceutical company.
Jean-Pierre
Wery, PhD.- Executive Vice President, Translational
Research, Crown Bioscience Inc.
Prior to joining CrownBio,. Dr. Wery was
Chief Scientific Officer at Monarch Life Sciences, a
company dedicated to the discovery and development of
protein biomarkers. Prior to joining Monarch, Dr. Wery
spent three years at Vitae Pharmaceuticals, Inc. where
he was VP of Computational Drug Discovery. Before joining
Vitae he worked for 12 years at Eli Lilly and Company
in various scientific and management positions. Dr.
Wery received his B.S. and Ph.D. in Physics from the
U. of Liege, Belgium. Following his Ph.D., he did postdoctoral
studies at Purdue University with Prof. Jack Johnson.
Dr. Wery has authored more than 50 abstracts and publications.
Scientific management
Michelle Xia,
PhD. - VP, Protein Science
Changnian (Charles) Liu, MD/PhD.- Senior Research Fellow,
Oncology
James Wu, PhD.- Executive Director, Protein Science
Qingyang (John) Gu, PhD.- Senior Director, Oncology
Qiming Shao, MD/PhD.- Senior Director, DMPKT, Pharmacology
Jian Wang, MD/PhD, - Senior Director, Pharmacology
Zhonghua Tang, PhD.- Director, Bioinformatics
Jinying Ning, MD/PhD.- Director, Cell Biology
|
